In patients with malignancies, the<unk><unk>  of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.
Tumor lysis syndrome cost-effectiveness of therapy
Tumor lysis syndrome diagnostic criteria
Tumor lysis syndrome primary prevention
Heparin-induced thrombocytopenia cost-effectiveness of therapy
Tumor lysis syndrome medical therapy
Hepatopulmonary syndrome future or investigational therapies
Acute liver failure future or investigational therapies
Reperfusion injury future or investigational therapies